Amgen/Apotex Appeals Arguments Aimed At April
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit said it will hear oral arguments on April 4 in Apotex Inc.'s appeal in a lawsuit brought by Amgen Inc., which has been trying to delay the marketing of the biosimilars maker's version of Neulasta (pegfilgrastim) – a product that has yet to receive the FDA's approval.
You may also be interested in...
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.